Cabozantinib

ClinicalAugust 10, 2026

Phase II Trial of Cabozantinib and Nivolumab in Advanced Melanoma and Head and Neck Cancer

The National Cancer Institute is conducting a phase II trial to evaluate the efficacy of cabozantinib and nivolumab in patients with advanced melanoma or squamous cell head and neck cancer.

Sponsor company

Mechanism of action

Recent signals(4)

Phase II/III Trial of Cabozantinib with Chemotherapy in Newly Diagnosed Osteosarcoma

Phase II/III Trial of Cabozantinib with Chemotherapy in Newly Diagnosed Osteosarcoma

Phase II Trial of Cabozantinib and Nivolumab in Advanced Melanoma and Head and Neck Cancer

Cabozantinib plus Nivolumab Shows Promise in Advanced Non-Clear Cell RCC

Upcoming milestones

Related catalysts(1)

Bristol Myers Squibb — cabozantinib

Indications

Therapeutic areas

Get signals before the market moves